RCE Establishes Strategic Partnership in South-East Asia
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has announced a strategic partnership with PT Etana Biotechnologies to accelerate clinical trials in Indonesia. The partnership aims to address antimicrobial resistance and improve access to novel infectious disease medicines in the region. This initiative is supported by both the Australian and Indonesian governments, highlighting a commitment to public health and innovation. The collaboration will facilitate access to a large patient population across ten ASEAN member states.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
- Murdoch Children's R327 Efficacy UTI in-vivo
- RCE Awarded Further $11.17m Advanced Overseas Finding
- RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
- Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
Later from Recce Pharmaceuticals
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- Recce Receives AUD $11.17m R&D Advance
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Patent Granted in Israel for RECCE Anti-Infectives
- Recce Pharmaceuticals - Business Update
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals